Extravan FDA Approval Status
Extravan (Travoprost 0.004% + Timolol 0.5% Fixed Combination (TTFC)) is a prostaglandin analogue and beta-blocker combination intended for use in the treatment of glaucoma.
In September 2004, Alcon, Inc. announced the receipt of an Approvable Letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for Extravan. While the combination is currently available in many countries, it remains commerically undeveloped in the United States.
Development Timeline for Extravan
|Sep 17, 2004||Alcon Receives Approvable Letter for Extravan|
|Jan 28, 2004||Alcon Files NDA for Combination Drug to Treat Glaucoma; Releases PreliminaryClinical Data at Major Ophthalmology Meeting|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.